Introduction {#sec1-1}
============

Colorectal cancer (CRC) is the third most common type of cancer \[[@ref1]\]. Although the median overall survival of patients with metastatic colorectal cancer has increased from 12 months to approximately 24 months over the past decade as a result of an improvement in systemic therapies including new chemotherapeutic agents, the 5-year survival is still pessimistic \[[@ref2]\].

A growing body of evidence supports the notion that only a small subset of cells within a solid tumour has 'stem-like' characteristics. These tumor-initiating cells, or cancer stem cells (CSCs), distinct from non-malignant stem cells, show low proliferative rates, high self-renewal capacity, propensity to differentiate into active proliferating tumour cells, and resistance to chemotherapy or radiation \[[@ref3]\]. Notably, owing to their high expression of DNA repair mechanisms, detoxifying enzymes, such as aldehyde dehydrogenase-1 (ALDH1), and molecular pumps, CSCs might survive radiochemotherapy; thus, possibly causing local recurrences and metastasis formation despite treatment \[[@ref4]\].

Despite the potentially high clinical relevance of CSCs, little is known about the prognostic value of the expression of putative CSC markers in colorectal cancers. Contradictory findings have been reported about the association between the expression of CD44 and tumour progression \[[@ref5]\].

Material and Methods {#sec1-2}
====================

A total of 60 stored, formalin fixed, paraffin embedded tumour biopsies from colectomy specimens of patients with colorectal cancer were collected from Kasr El Aini Hospital and multiple private laboratories with the permission of the head of these labs, the specimens were anonymous for confidentiality and replaced by numbers.

The site of the tumour was classified into the right colon (cecum, ascending colon, hepatic flexure and transverse colon), left colon (splenic flexure, descending colon and sigmoid) and rectum, while the size of the tumour was calculated as the length of the largest diameter. Size and site, as well as age and sex, were obtained from the pathology reports of the patients. Undifferentiated carcinoma cases were documented immunohistochemically from where the cases were recruited.

The tumour extension into other organs, distant metastasis if present and the lymph node status were also obtained from the diagnosis present in the pathology reports (clinical data of distant metastasis in other organs were also obtained from the patient's sheet).

The paraffin blocks of the tumour were serially sectioned at 4 μm thickness. Afterwards, they were stained with routine hematoxylin-eosin stain for pathological examination and morphologic classification of the colorectal cancer according to the recommendations of the World Health Organization \[[@ref6]\] including histological types, subtypes, tumor grade, depth of tumor invasion, perineural invasion and lymphovascular emboli while staging was performed using modified Dukes' classification of the disease \[[@ref7]\], and TNM staging system \[[@ref8]\] for each case.

Paraffin section from each case was processed for immunostaining using CD44 Std. / HCAM AB-4 (0.7 ml. of antibody prediluted 0.05 mol/L Tris-HCl, pH 7.6 containing stabilising protein and 0.015 mol/L sodium azide -- Thermo Fisher Scientific. UK) and Econo Tek HRP Anti-Polyvalent (DAP) ready-to-use (Scy Tek Laboratories inc. USA) detection system.

CD44 stained sections were examined at high power for immunohistochemical expression and were divided into negative (no immunoreactivity in any cells) and positive (membrane and/or cytoplasm immunoreactivity present) \[[@ref9]\].

The antibody labels approximately 90% of all lymphocytes, both T cells and B cells \[[@ref10]\], were positively stained lymphocytes were used as an internal positive control.

In colorectal cancer, metastasis was almost exclusively a property of the CSCs that exhibited long-term self-renewing capacity \[[@ref11]\]. So we used to divide the histological types, tumour grade and invasiveness (T) into metastatic and non-metastatic groups to correlate them with the rate of CD44 expression.

Statistical methods {#sec2-1}
-------------------

SPSS version 18.0 was used for data management. Mean and standard deviation described quantitative data and non-parametric t-test compared two independent groups and non-parametric ANOVA compared more than two groups. Chi-square /Fisher exact test proportion independence and the p-value are set significant at 0.05 level.

Results {#sec1-3}
=======

The characteristics of the study population are shown in [Table 1](#T1){ref-type="table"}. The subjects consisted of 29 males (48.3%) and 31 females (51.7%), with a mean age of 54.86 years (median, 56 years; range, 25--75 years) and a mean tumour size of 6.25 cm (median, 6 cm; range, 2--16 cm). Most of the cases were adenocarcinoma (75%) followed by mucinous carcinoma (21.7%) and undifferentiated carcinoma (3.3%). The tumour was distributed regarding the site; (75%) in the colon while (25%) of the cases were found in the rectum. The TNM staging is applied according to the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) where it encodes the extent of the primary tumor (T), regional lymph nodes (N), and distant metastases (M) 3, 17, 31, and 9 patients had stage I--IV cancers, respectively \[[@ref8]\]. According to Modified Dukes' classification \[[@ref7]\] cases in this study are classified into 20 cases (33.3%) B, 31 cases (51.7%) stage C and 9 cases (15%) stage D with no cases of stage A.

###### 

Description of set of patients and CD44 rate of expression in the study

                                                                    No. (%)       CD44 expression   P-value      
  ---------------------------------------------------- ------------ ------------- ----------------- ------------ ---------------------------------------------
  Patients                                                          60            25 (41.7%)        35 (58.3%)   
                                                                                                                 
  Gender:                                                                                                        
  Male                                                              29 (48.3%)    16 (55.2%)        13 (4.48%)   0.63
  Female                                                            31 (51.7%)    19 (61.3%)        12 (38.7%)   
                                                                                                                 
  Age:                                                                                                           
   Range                                                            25-75 yrs                                    0.07
   Mean                                                             54.867        57.086            51.760       
   Std. deviation                                                   11.0415       8.8695            13.0776      
                                                                                                                 
  Tumour site:                                                                                                   
   Colon                                                            45 (75%)      30 (66.7%)        15 (33.3%)   [0.02[\*](#t1f1){ref-type="table-fn"}]{.ul}
   Rectum                                                           15 (25%)      5 (33.3%)         10 (66.7%)   
                                                                                                                 
  Tumour size:                                                                                                   
   Range                                                            2-16 cm.                                     0.29
   Mean                                                             6.250         5.929             6.700        
   Std. deviation                                                   2.5669        2.1287            3.0687       
                                                                                                                 
  Histological type:                                                                                             
   Adenocarcinoma                                                   45 (75%)      31 (68.9%)        14 (31.1%)   [0.01[\*](#t1f1){ref-type="table-fn"}]{.ul}
   Mucinous                                                         13 (21.7%)    4 (30.8%)         9 (69.2%)    
   Undifferentiated                                                 2 (3.3%)      0 (0%)            2 (100%)     
                                                                                                                 
  Adenocarcinoma: [\*\*](#t1f2){ref-type="table-fn"}                45 (75%)      31 (68.9%)        14 (31.1%)   1.0
   Metastatic                                                       8             6 (75%)           2 (25%)      
   Non metastatic                                                   37            25 (67.6%)        12 (32.4%)   
                                                                                                                 
  Mucinous: [\*\*](#t1f2){ref-type="table-fn"}                      13 (21.7%)    4 (30.8%)         9 (69.2%)    0.38
   Metastatic                                                       1             1 (100%)          0 (0%)       
   Non metastatic                                                   12            3 (25%)           9 (75%)      
                                                                                                                 
  Tumor grade: [\*\*](#t1f2){ref-type="table-fn"}                                                                
   Grade 1                                                          0 (0%)        0 (0%)            0 (0%)       0.10
   Grade 2                                                          53 (83.3%)    33 (62.3%)        20 (37.7%)   
   Grade 3                                                          7 (11.7%)     2 (28.6%)         5 (71.4%)    
                                                                                                                 
  Grade 2: [\*\*](#t1f2){ref-type="table-fn"}                       53 (83.3%)    33 (62.3%)        20 (37.7%)   0.7
   Metastatic                                                       8             6 (75%)           2 (25%)      
   Non metastatic                                                   45            27 (60%)          18 (40%)     
                                                                                                                 
  Grade 3: [\*\*](#t1f2){ref-type="table-fn"}                       7 (11.7%)     2 (28.6%)         5 (71.4%)    0.29
   Metastatic                                                       1             1 (100%)          0 (0%)       
   Non metastatic                                                   6             1 (16.7%)         5 (83.3%)    
                                                                                                                 
  Tumor extent (T):                                                                                              
                                                                                                                 
   T1                                                  T1+T2        1 (1.7%)      7 (77.8%)         2 (22.2%)    0.52
   T2                                                  8 (13.3%)                                                 
                                                                                                                 
   T3                                                  T3           45 (75%)      25 (55.6%)        20 (44.4%)   
                                                                                                                 
   T4a                                                 T4a+T4b      3 (5%)        3 (50%)           3 (50%)      
   T4b                                                 3 (5%)                                                    
                                                                                                                 
  T1+T2: [\*\*](#t1f2){ref-type="table-fn"}                         9 (15%)       7 (77.8%)         2 (22.2%)    1.0
   Metastatic                                                       1             1 (100%)          0 (0%)       
   Non metastatic                                                   8             6 (75%)           2 (25%)      
                                                                                                                 
  T3: [\*\*](#t1f2){ref-type="table-fn"}                            45 (75%)      25 (55.6%)        20 (44.4%)   0.36
   Metastatic                                                       5             4 (80%)           1 (20%)      
   Non metastatic                                                   40            21 (52.5%)        19 (47.5%)   
                                                                                                                 
  T4a+T4b: [\*](#t1f1){ref-type="table-fn"}                         6 (10%)       3 (50%)           3 (50%)      1.0
   Metastatic                                                       3             2 (66.7%)         1 (33.3%)    
   Non metastatic                                                   3             1 (33.3%)         2 (66.7%)    
                                                                                                                 
  Lymph node status (N):                                                                                         
                                                                                                                 
   N0                                                  N0           22 (36.7%)    15 (68.2%)        7 (31.8%)    0.55
                                                                                                                 
   N1a                                                 N1a+N1b      15 (25%)      12 (60%)          8 (40%)      
   N1b                                                 5 (8.3%)                                                  
                                                                                                                 
   N2a                                                 N2a+N2b      11 (18.3 %)   8 (44.4%)         10 (55.6%)   
   N2b                                                 7 (11.7%)                                                 
                                                                                                                 
  Distant metastasis (M):                                                                                        
                                                                                                                 
  M0                                                   51 (85%)     29 (56.9%)    22 (43.1%)        0.72         
                                                                                                                 
  M1a                                                  4 (6.7%)     6 (75%)       3 (25%)                        
  M1b                                                  5 (8.3%)                                                  
                                                                                                                 
  Stage grouping:                                                                                                
  I                                                    3 (5%)       2 (66.7%)     1 (33.3%)         0.78         
  II                                                   17 (28.4%)   11 (64.7%)    6 (35.3%)                      
  III                                                  31 (51.6%)   16 (51.6%)    15 (48.4%)                     
  IV                                                   9 (15%)      6 (66.7%)     3 (33.3%)                      
                                                                                                                 
  Modified Dukes':                                                                                               
  Stage A                                              0 (0%)       0 (0%)        0 (0%)            0.55         
  Stage B                                              20 (33.3%)   13 (65%)      7 (35%)                        
  Stage C                                              31 (51.7%)   16 (49.6%)    15 (50.4%)                     
  Stage D                                              9 (15%)      6 (66.7%)     3 (33.3%)                      
                                                                                                                 
  Perineural invasion:                                                                                           
  Absent                                               52 (86.7%)                                                
  Present                                              8 (13.3%)                                                 
                                                                                                                 
  Lympho-vascular emboli:                                                                                        
  Absent                                               58 (96.7%)                                                
  Present                                              2 (3.3%)                                                  

statistically significant p-value;

pathological parameters such as the grade, histological types and invasiveness (T) of the tumour were classified into metastatic and non-metastatic groups, the metastatic groups showed a higher rate of CD44 expression than non-metastatic ones.

Expression of CD44s in primary tumour was demonstrated in 58.3% (35/60). The relationships between tumour CD44s expression and the clinicopathological features of CRC are summarised in [Table 1](#T1){ref-type="table"}.

The characteristics of the study population are shown in [Table 1](#T1){ref-type="table"}. The subjects consisted of 29 males (48.3%) and 31 females (51.7%), with a mean age of 54.86 years (median, 56 years; range, 25--75 years) and a mean tumour size of 6.25 cm (median, 6 cm; range, 2--16 cm). Most of the cases were adenocarcinoma (75%) followed by mucinous carcinoma (21.7%) and undifferentiated carcinoma (3.3%). The tumour was distributed regarding the site; (75%) in the colon while (25%) of the cases were found in the rectum. The TNM staging is applied according to the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) where it encodes the extent of the primary tumor (T), regional lymph nodes (N), and distant metastases (M) 3, 17, 31, and 9 patients had stage I--IV cancers, respectively \[[@ref8]\].

According to Modified Dukes' classification \[[@ref7]\] cases in this study are classified into 20 cases (33.3%) B, 31 cases (51.7%) stage C and 9 cases (15%) stage D with no cases of stage A.

Expression of CD44s in primary tumour was demonstrated in 58.3% (35/60). The relationship between tumour CD44s expression and the clinicopathological features of CRC is summarised in [Table 1](#T1){ref-type="table"}.

![Adenocarcinoma GII with strong CD44 expression; membranous and focal cytoplasmic staining (x400)](OAMJMS-4-543-g001){#F1}

CD44 showed a higher rate of expression in colon rather than rectal cases (p-value 0.02) and a higher rate of expression in adenocarcinoma cases than mucinous and undifferentiated carcinoma cases (p-value 0.01). The correlation was statistically significant by Chi-square /Fisher exact test proportion independence (p-value is set significant at 0.05 level).

![Mucinous carcinoma GII with strong CD44 expression and evident lymphocyte staining as internal control (x100)](OAMJMS-4-543-g002){#F2}

The CD44 rate of expression showed statistically insignificant correlation with distant metastasis (M) and the metastatic group of all parameters including grade, histological types and invasiveness. Whereas it showed statistically insignificant inverse correlation with the grade, invasiveness (T), lymph node status (N), TNM stage grouping and modified Dukes' staging (except for stage IV and stage D respectively which represent the metastatic stage) (p-value \> 0.05).

![Undifferentiated carcinoma showing negative CD44 expression with focal staining of the lymphocytes which acts as internal control (x400)](OAMJMS-4-543-g003){#F3}

No association was detected between CD44 expression and age, gender, tumour size, perineural invasion or lymphovascular invasion (p-value \> 0.05).

Discussion {#sec1-4}
==========

Cancer-related death from colorectal cancer is usually due to the development of distant metastasis. Approximately 70% of all patients diagnosed with CRC undergo potentially curative surgery, but half of those present with or develop advanced local disease or metastases \[[@ref12]\]. Although several prognostic factors exist, including clinical staging classification, a more specific recognition marker for CRC with high metastatic potential would provide useful information for evaluating adjuvant therapies \[[@ref13]\].

The concept of the contribution of colorectal cancer stem cells to tumour development is widely accepted, but the relation of individual CSC markers expression to disease prognosis is still not completely clear \[[@ref14]\].

The relation between the site of the primary tumor and the rate of CD44 expression was statistically significant, where rectal tumors showed lower rate of CD44 expression (33.3%) than colonic tumors (66.7%) with slightly higher rate of expression in the right colon (70.8%) than in the left colon (61.9%) which is consistent with the results of \[[@ref15]\] who found lower rate of CD44 expression in rectum (44.4%) than colon (64.4%). However, other studies showed higher rate of CD44 expression in rectum (48%) than colon (21.2%) \[[@ref16]\], rectum (53.8%) and colon (30.8%) \[[@ref13]\] and in rectum and left colon (53.8%) each then right colon (45.2%) (Al-Maghraby et al., 2012) \[[@ref17]\].

The rate of CD44 expression varied according to histological type where there was statistically significant correlation between the rate of CD44 expression and the histological type. Adenocarcinoma cases showed the highest rate of CD44 expression (68.9%), followed by mucinous carcinoma (30.8%) then undifferentiated carcinoma which showed no CD44 expression. While other studies found a higher rate of CD44 expression in mucinous carcinoma (61.1%) than adenocarcinoma (49.5%) \[[@ref18]\] and also higher in mucinous carcinoma (85.7%) than adenocarcinoma (55.9%) \[[@ref15]\].

The role of CD44 as CSC marker itself is under debate, where Liu et al. (2014) \[[@ref19]\] stated that CD44 is of functional importance for cancer initiation, progression, maintenance of the properties of CSC. While Pitule et al. (2014) \[[@ref14]\] suggested that the use of CD44 as a single prognostic marker of CRC behaviour is impossible. Moreover Galizia et al. (2012) \[[@ref20]\] results showed that evaluation of combined CD133/CD44 expression could be useful to identify putative colorectal CSCs than CD133 and CD44 individually which failed to identify colorectal CSCs.

The inconsistency and controversy of results from various studies correlating CD44 immunoexpression in relation to clinicopathological parameters may be related to technical factors, such as the type of antibody, differences in immunostaining method, type of tissue blocks, immunostaining scoring method and the cut-off for negative/positive or low/high \[[@ref17]\].

We can also suggest another cause of controversy of results; which is the different functions of CD44 that may be presented in some tumours and absent in others. This suggestion is supported by Gunthert (1996) \[[@ref21]\] who mentioned that during the malignant transformation process, and depending on the origin, the cell either gains or loses its ability to express some forms of this adhesion molecule. Thus, in human malignancies, it seems that the staining pattern for CD44 isoforms differs between the different tumour types, supporting the concept that the growth advantage for cancer cells contributed by CD44 depends on the cellular background.

A limitation of this study was the small scale of cases and unspecified selection of single parameter such as; studying CD44 expression in relation to recurrent cases, certain histological type, grade or stage (whether of invasiveness, lymph node status or metastasis) or even in relation to age, sex or site individually.
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